NEW HYBRID STRUCTURES BASED ON MEMANTHINE AND EDARAVONE MOLECULES

V. V. Grigoriev; Григорьев В. В.; A. Yu. Aksinenko; Шевцова Е. Ф.; E. F. Shevtsova; Аксиненко А. Ю.; T. V. Goreva; Веселов И. М.; I. M. Veselov; Горева Т. В.; A. V. Gabrelyan; Габрельян А. В.; S. O. Bachurin; Бачурин С. О.

doi:10.31857/S2686738923600413

NEW HYBRID STRUCTURES BASED ON MEMANTHINE AND EDARAVONE MOLECULES

作者: Grigoriev V.¹, Aksinenko A.¹, Shevtsova E.¹, Goreva T.¹, Veselov I.¹, Gabrelyan A.¹, Bachurin S.¹
隶属关系:
1. Institute of Physiologically Active Substances, Federal State Budgetary Institution of Science, Federal Research Center for Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences
期: 卷 512, 编号 1 (2023)
页面: 466-469
栏目: Articles
URL: https://journals.rcsi.science/2686-7389/article/view/140857
DOI: https://doi.org/10.31857/S2686738923600413
EDN: https://elibrary.ru/PYWTWG
ID: 140857

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅存取

详细
作者简介
参考
补充文件
统计

详细

New hybrid structures based on memantine and edaravone molecules, in which the pyrazolone ring and adamantane fragments are linked by an alkyl linker, have been synthesized. It was found that in addition to the ability to block the intrachanal site of NMDA receptors, new hybrid compounds exhibit the property of blockers of the allosteric site of NMDA receptors, which is not inherent in memantine and edaravone preparations. The most active hit compound was determined, which, along with the properties of a two-site blocker of the NMDA receptor, exhibits a pronounced activity as an inhibitor of lipid peroxidation, similar to the drug edaravone.

关键词

amyotrophic lateral sclerosis, Alzheimer’s disease, memantine, edaravone, 1-aminoadamantanes, NMDA receptors, oxidative stress, lipid peroxidation

参考

P.V. Peplow, B. Martinez, T.A. Gennarelli, Eds. Neurodegenerative Diseases Biomarkers: Towards Translating Research to Clinical Practice. Springer US, 2021, 565 p.
Blasco H., Mavel S., Corcia P., Gordon P.H. // Curr Med Chem. 2014. V. 21. № 31. P. 3551–3375.
Wang R., Reddy P.H. // J Alzheimers Dis. 2017. V. 57. № 4. P. 1041–1048.
Ahmed H., Haider A., Ametamey S.M. // Expert Opin Ther Pat. 2020. V. 30. № 10. P. 743–767.
Tikhonova I.G., Baskin I.I., Palyulin V.V., Zefirov N.S., Bachurin S.O. // J. Med. Chem. 2002. V. 45. № 18. P. 3836–3843.
Lipton S.A. // Nat. Rev. Drug Discov. 2006. V. 5. № 2. P. 160–170.
Jiang J., Wang Y., Deng M. // Front Pharmacol. 2022. V. 28. № 13. 1054006.
Angelova P.R., Esteras N., Abramov A.Y. // Med Res Rev. 2021. V. 41. № 2. P. 770–784.
Jaiswal M.K. // Med Res Rev. 2019. V. 39. № 2. P. 733–748.
Savelieff M.G., Nam G., Kang J., et al. // Chem Rev. 2019. V. 119. № 2. P. 1221–1322.
Bachurin S.O., Makhaeva G.F., Shevtsova E.F., et al. // Molecules. 2021. V. 26. 5527.
Bachurin S.O., Shevtsova E.F., Makhaeva G.F., et al. // Int J Mol Sci. 2022. V. 23. № 22. 13925.
Аксиненко А.Ю., Горева Т.В., Епишина Т.А., Бачурин С.О. // Изв. АН. Сер. хим., 2022. № 8. С. 1794–1800.
Махаева Г.Ф., Шевцова Е.Ф., Болтнева Н.П., и др. // Доклады РАН, Биохимия, биофизика, 2019. Т. 484. № 1. С. 104–108. https://doi.org/10.7868/S0205-961448410104-108
Ugale V., Dhote A., Narwade R., et al. // CNS & Neurological Disorders – Drug Targets. 2021. V. 20. Iss. 9.